Abstract: A drug delivery system and methods of using such for delivering a peglyated therapeutic agent to brain. The drug delivery system may comprise an antibody, which binds polyethylene glycol (PEG), wherein the antibody is embedded in a hydrogel, which may comprises one or more biodegradable polymers, up to 60% of which contain inter-chain or intra-chain covalent crosslinks. The amount of the antibody in the drug delivery system can be about 1-2 ?g per ?l of the hydrogel.

Abstract: A method of facilitating the delivery of an agent across the blood-brain barrier (BBB) of a subject, the method involving the use of a low dose of vascular endothelial growth factor (VEGF) polypeptide. In some embodiments, the VEGF polypeptide can be given to the subject before and after administration of the agent at multiple doses.

Abstract: A drug delivery system and methods of using such for delivering a peglyated therapeutic agent to heart. The drug delivery system may comprise an antibody embedded in a hydrogel, comprising one or more biodegradable polymers, up to about 60% of which contain inter-chain or intra-chain covalent crosslinks.

Abstract: Disclosed herein is a method of facilitating the delivery of an agent across blood-brain barrier (BBB) of a subject. The method includes administering to the subject in sequence or concomitantly, an effective amount of a growth factor selected from the group consisting of, vascular endothelial growth factor (VEGF), insulin-like growth factor I (IGF-1), IGF-II, a portion thereof and a combination thereof; and an agent that is any of a therapeutic agent or an imaging agent. The administered amount of the growth factor is capable of transiently increasing BBB permeability of the subject and thereby allowing the agent to be delivered across BBB. Also disclosed herein is a method of treating a subject suffering from a brain tumor, a brain stroke, a neuropsychiatric disorder and/or a neurodegenerative disease.

Abstract: A drug delivery system and methods of using such for delivering a peglyated therapeutic agent to brain. The drug delivery system may comprise an antibody, which binds polyethylene glycol (PEG), wherein the antibody is embedded in a hydrogel, which may comprises one or more biodegradable polymers, up to 60% of which contain inter-chain or intra-chain covalent crosslinks. The amount of the antibody in the drug delivery system can be about 1-2 ?g per ?l of the hydrogel.

Abstract: A drug delivery system and methods of using such for delivering a peglyated therapeutic agent to heart. The drug delivery system may comprise an antibody embedded in a hydrogel, comprising one or more biodegradable polymers, up to about 60% of which contain inter-chain or intra-chain covalent crosslinks.

Abstract: Disclosed herein is a method of facilitating the delivery of an agent across blood-brain barrier (BBB) of a subject. The method includes administering to the subject in sequence or concomitantly, an effective amount of a growth factor selected from the group consisting of, vascular endothelial growth factor (VEGF), insulin-like growth factor I (IGF-1), IGF-II, a portion thereof and a combination thereof; and an agent that is any of a therapeutic agent or an imaging agent. The administered amount of the growth factor is capable of transiently increasing BBB permeability of the subject and thereby allowing the agent to be delivered across BBB. Also disclosed herein is a method of treating a subject suffering from a brain tumor, a brain stroke, a neuropsychiatric disorder and/or a neurodegenerative disease.